Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
1996 | Lack of NK cells and related cytokines in pleural effusion. | Chen, YM; Whang-Peng, J; Yang, WK; Hung, YM; Lin, WC; Kuo, BI; Perng, RP | Zhonghua yi xue za zhi = Chinese medical journal 58(3), 156-162 | | | |
2011 | Long-Term Results of a Randomized, Observation-Controlled, Phase III Trial of Adjuvant Interferon Alfa-2b in Hepatocellular Carcinoma After Curative Resection | Chen, LT; Chen, MF; Li, LA ; Lee, PH; Jeng, LB; Lin, DY; Wu, CC; Mok, KT; Chen, CL; Lee, WC; Chau, GY; Chen, YS; Lui, WY; Hsiao, CF; Whang-Peng, J; Chen, PJ | ANNALS OF SURGERY 255(1), 8-17 | | | |
1997 | Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. | Chen, WS; Chen, JY; Liu, JM; Lin, WC; King, KL; Whang-Peng, J; Yang, WK | International journal of cancer 74(4), 470-4 | | | |
2016 | Preclinical investigation of Ibrutinib, a Bruton’s kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes | Wei, L; Su, YK; Lin, CM; Chao, TY; Huynh, TT; Jan, HJ; Whang-Peng, J; Chiou, JF; Wu, AT; Hsiao, M | Oncotarget 7(43), 69961-975 | | | |
2008 | Quality of life after curative gastrectomy for gastric cancer in a randomized controlled trial | Wu, C-W; Chiou, J-M ; Ko, F-S; Lo, S-S; Chen, J-H; Lui, W-Y; Whang-Peng, J | British Journal of Cancer 98, 54-59 | | | |
1997 | Restoration of the immunocompetence by IL-2 activation and TCR-CD3 engagement of the in vivo anergized tumor-specific CTL from lung cancer patients. | Chen, YM; Yang, WK; Whang-Peng, J; Tsai, WY; Hung, YM; Yang, DM; Lin, WC; Perng, RP; Ting, CC | Journal of immunotherapy 20(5), 354-64 | | | |
1998 | S- and G2-phase cell cycle arrests and apoptosis induced by ganciclovir in murine melanoma cells transduced with herpes simplex virus thymidine kinase. | Wei, SJ; Chao, Y; Hung, YM; Lin, WC; Yang, DM; Shih, YL; Ch’ang, LY; Whang-Peng, J; Yang, WK | Experimental cell research 241(1), 66-75 | | | |
2018 | The apple polyphenol phloretin inhibits breast cancer cell migration and proliferation via inhibition of signals by type 2 glucose transporter. | Wu, KH; Ho, CT; Chen, ZF; Chen, LC; Whang-Peng, J; Lin, TN; Ho, YS | Journal of food and drug analysis 26(1), 221-231 | | | |